{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:28:54Z","timestamp":1781152134514,"version":"3.54.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Mass distributions of azithromycin for trachoma have been associated with secondary benefits, including reductions in child mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>In the Partnership for the Rapid Elimination of Trachoma cluster-randomized trial in Niger, 24 communities were randomized to annual treatment of everyone and 24 communities were randomized to biannual treatment of children under 12 for 3 years (clinicaltrials.gov, NCT00792922). Treatment was a single dose of directly observed oral azithromycin (20\u2009mg\/kg up to 1\u2009g in adults). Vital status was assessed during annual census and monitoring visits. In this prespecified secondary analysis, we compared the mortality rate among children 6 months to less than 5 years of age by treatment arm using negative binomial regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Among children 6 months to less than 5 years of age, 404 deaths occurred during the study period. The mortality rate was 35.6 deaths per 1000 person-years (231 deaths, 95% CI: 30.9\u201340.9) in the annual arm and 29.0 deaths per 1000 person-years (173 deaths, 95% CI: 24.8\u201333.8) in the biannual arm. The mortality rate ratio comparing children in the biannual arm to the annual arm was 0.81 (95% CI: 0.66\u20131.00,<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.07; primary outcome). The mortality rate ratio comparing children who died from infectious causes in the biannual arm to the annual arm was 0.73 (95% CI: 0.57\u20130.94;<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.02). No adverse events were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>This secondary analysis of a cluster-randomized trial found a nonsignificant 19% decrease in mortality among children 6 months to less than 5 years of age who received biannual azithromycin compared with children who received annual azithromycin. This study was conducted in a high mortality, trachoma-endemic area; thus, results may be specific to this environment only. In addition, the trial was neither designed nor powered to detect a mortality effect, and we cannot rule out the possibility that mortality differences resulted from bias.<\/jats:p><\/jats:sec>","DOI":"10.1097\/inf.0000000000001992","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T14:15:53Z","timestamp":1521641753000},"page":"1082-1086","source":"Crossref","is-referenced-by-count":17,"title":["Childhood Mortality After Mass Distribution of Azithromycin"],"prefix":"10.1097","volume":"37","author":[{"given":"Kieran S.","family":"O\u2019Brien","sequence":"first","affiliation":[{"name":"Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Y.","family":"Cotter","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdou","family":"Amza","sequence":"additional","affiliation":[{"name":"Programme FSS\/Universit\u00e9 Abdou Moumouni de Niamey, Programme National de Sant\u00e9 Oculaire, Niamey, Niger"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boubacar","family":"Kadri","sequence":"additional","affiliation":[{"name":"Programme FSS\/Universit\u00e9 Abdou Moumouni de Niamey, Programme National de Sant\u00e9 Oculaire, Niamey, Niger"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beido","family":"Nassirou","sequence":"additional","affiliation":[{"name":"Programme FSS\/Universit\u00e9 Abdou Moumouni de Niamey, Programme National de Sant\u00e9 Oculaire, Niamey, Niger"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Stoller","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Zhou","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila K.","family":"West","sequence":"additional","affiliation":[{"name":"Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Marlyland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Bailey","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Keenan","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California"},{"name":"Ophthalmology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis C.","family":"Porco","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California"},{"name":"Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Lietman","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California"},{"name":"Ophthalmology"},{"name":"Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","first-page":"Cd001860","article-title":"Antibiotics for trachoma.","author":"Evans","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/INF.0b013e31824155c9","article-title":"Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children.","volume":"31","author":"Coles","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4269\/ajtmh.2011.11-0046","article-title":"Association of mass treatment with azithromycin in trachoma-endemic communities with short-term reduced risk of diarrhea in young children.","volume":"85","author":"Coles","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1086\/341414","article-title":"Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal.","volume":"35","author":"Fry","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3201\/eid2006.131302","article-title":"Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania.","volume":"20","author":"Schachterle","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1128\/AAC.49.11.4804-4806.2005","article-title":"Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis.","volume":"49","author":"Solomon","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/infdis\/jiu046","article-title":"Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?","volume":"210","author":"West","year":"2014","journal-title":"J Infect Dis"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3201\/eid1507.081563","article-title":"Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma.","volume":"15","author":"Hong","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"917370","DOI":"10.1155\/2015\/917370","article-title":"Antibiotic Resistance in Streptococcus pneumoniae after azithromycin distribution for trachoma.","volume":"2015","author":"Ho","year":"2015","journal-title":"J Trop Med"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/ije\/dyu062","article-title":"Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control.","volume":"43","author":"Seidman","year":"2014","journal-title":"Int J Epidemiol"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3389\/fmicb.2016.01420","article-title":"Longitudinal comparison of antibiotic resistance in diarrheagenic and non-pathogenic Escherichia coli from young Tanzanian children.","volume":"7","author":"Seidman","year":"2016","journal-title":"Front Microbiol"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/cid\/cir069","article-title":"Childhood mortality in a cohort treated with mass azithromycin for trachoma.","volume":"52","author":"Keenan","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2009.1266","article-title":"Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.","volume":"302","author":"Porco","year":"2009","journal-title":"JAMA"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17441690903352572","article-title":"Seasonality of childhood infectious diseases in Niono, Mali.","volume":"5","author":"Findley","year":"2010","journal-title":"Glob Public Health"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/09286586.2010.545500","article-title":"Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.","volume":"18","author":"Stare","year":"2011","journal-title":"Ophthalmic Epidemiol"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"e1586","DOI":"10.1371\/journal.pntd.0001586","article-title":"Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial.","volume":"6","author":"Amza","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/cid\/ciw810","article-title":"A cluster-randomized trial to assess the efficacy of targeting trachoma treatment to children.","volume":"64","author":"Amza","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/8451","article-title":"Global elimination of trachoma: how frequently should we administer mass chemotherapy?","volume":"5","author":"Lietman","year":"1999","journal-title":"Nat Med"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"010601.","DOI":"10.7189\/jogh.06.010601","article-title":"Validating hierarchical verbal autopsy expert algorithms in a large data set with known causes of death.","volume":"6","author":"Kalter","year":"2016","journal-title":"J Global Health"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(09)60323-8","article-title":"Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial.","volume":"373","author":"House","year":"2009","journal-title":"Lancet"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(16)31575-6","article-title":"Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015.","volume":"388","year":"2016","journal-title":"Lancet"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201811000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T22:23:49Z","timestamp":1751495029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201811000-00003"}},"subtitle":["A Secondary Analysis of the PRET Cluster-randomized Trial in Niger"],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001992","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}